Specialized in nanotechnologies applied to cancer treatment, the French biotech Nanobiotix is making a lot of noise on the stock market. And for good reason, because between July 2025 and May 2026, Nanobiotix stock rose by nearly 1,000%, climbing from 4.30 euros to over 47 euros, before suffering a sharp 58% stock correction. Could this drop represent an investment opportunity or, on the contrary, signal new difficulties?
With its strategic partnership with Johnson & Johnson and the progress of its experimental treatment NBTXR3 against cancer, Nanobiotix shares have many strengths. But investing in Nanobiotix stock remains a risky bet. So, should one buy Nanobiotix stock in late 2026?
Discover our comprehensive analysis with the latest financial results, the company’s outlook, fundamental and technical analysis, as well as our view on the potential of Nanobiotix stock for late 2026 and 2027.
Who is Nanobiotix? History and Key Figures
The idea behind Nanobiotix is fairly simple to understand: to make radiotherapy more effective in the fight against cancer. But to achieve this, the company bets on an unusual technology: injecting directly into tumors tiny hafnium oxide particles. When exposed to radiation, these particles help strengthen the effects on cancer cells.
It is on this principle that NBTXR3, Nanobiotix’s main treatment, is based. It is currently the subject of several clinical trials, notably for certain head and neck cancers.
The project even convinced Johnson & Johnson, which signed a major licensing agreement with Nanobiotix. The challenge now is to prove that this technology can deliver on its promises at scale. While the prospects are interesting, the path to potential commercialization remains long.
Key Information about Nanobiotix
| Key Information | Data |
| Company | Nanobiotix SA |
| Stock ticker | NANO (Paris) / NBTX (Nasdaq) |
| ISIN | FR0011341205 |
| Main listing exchanges | Euronext Paris (Compartiment B) and Nasdaq Global Select Market (ADS) |
| Industry | Biotechnologies, nanomedicine and oncology |
| Founded | 2003 |
| Headquarters | Paris, France |
| CEO | Laurent Levy, cofounder |
| Geographic presence | France, United States and Germany |
| Market capitalization | €1.01 billion as of October 14, 2026 |
| Stock index | Euronext Tech Leaders |
| Number of employees | 97 employees |
What are Nanobiotix’s latest results in 2026?
Nanobiotix published its first-half 2026 results on September 24. And as is often the case with biotechs still developing their therapies, the accounts remain in the red. Revenues fell sharply compared with the previous year, but it should be noted that those of 2025 benefited from an exceptional element related to the Johnson & Johnson agreement. The comparison is thus somewhat misleading.
On the expense side, Nanobiotix slightly reduced its research and development costs and administrative expenses, without managing to curb losses. The good news mainly comes from its cash position, which was strengthened by an €86 million fundraising in May 2026. According to the company’s projections, this should allow it to continue its activities until 2029.
Main figures of H1 2026 results for Nanobiotix
| Indicator | Value |
| Revenues and other income | €5.6 million |
| R&D expenses | €12.7 million |
| G&A expenses | €10.8 million |
| Net loss | €-34.3 million |
| Net loss per share | €-0.70 |
| Cash and cash equivalents as of June 30, 2026 | €110.9 million |
| Fundraising (May 2026) | €86 million |
| Financing horizon | Until 2029 |
Commentary from Laurent Levy, CEO of Nanobiotix :
The JNJ-1900 program (NBTXR3) continued to produce encouraging data in several indications. Historical shareholders as well as new investors also expressed their confidence in our vision through our recent fundraising.
What is Nanobiotix’s position in the health sector in 2026?
On the market for cancer treatments, Nanobiotix is trying to carve out a niche alongside giants like Roche, AstraZeneca or Merck, which invest billions in oncology research. But rather than seeking to develop a new traditional anticancer drug, the French biotech has chosen a different path: using nanotechnologies to improve the effectiveness of radiotherapy.
This strategy allows it to position itself in a market where medical needs remain considerable. And the partnership signed with Johnson & Johnson gives it resources that would have been difficult to mobilize on its own.
Yet Nanobiotix does not operate in the same category as large pharmaceutical laboratories. Its technology must still prove itself at scale, and the results of clinical trials will be decisive to hope for a lasting foothold in the health sector.
Commentary from Laurent Levy, CEO of Nanobiotix :
The progress achieved in the first half of 2026 continues to reinforce our conviction that a physics-based approach to designing and developing nanotherapies could revolutionize treatment options for millions of patients worldwide.
Should you invest in Nanobiotix stock by end-2026? Café de la Bourse’s view and fundamental analysis
In our view, it is still too early to buy Nanobiotix stock on the market, at least for an investor seeking a minimum of visibility. The market has already shown how quickly this biotech can surge, then brutally correct. And nothing guarantees that the current decline in Nanobiotix’s stock is over.
That said, we are not necessarily pessimistic about the long-term potential of Nanobiotix’s stock. The real question will be whether the next clinical advances of NBTXR3, notably the results of ongoing trials and the progression of development with Johnson & Johnson, will meet investors’ expectations. Positive clinical data on NBTXR3 could quickly rekindle interest in Nanobiotix stock, while disappointing results or delays in development could trigger a new wave of selling for Nanobiotix.
We would therefore favor a wait-and-see stance, even if it means missing the start of a possible rebound in Nanobiotix stock. More speculative investors could consider a gradual entry, accepting a significant risk of loss. This scenario remains hypothetical and does not constitute investment advice.
How to invest in Nanobiotix stock in practice?
To invest in Nanobiotix stock on the stock market, the simplest approach is to buy directly through a stockbroker such as XTB, eToro or Trade Republic, provided the stock is available on the chosen platform. The purchase can be made from a regular securities account (CTO), but also from a Plan d’Épargne en Actions (PEA), since Nanobiotix is a French company eligible for this tax wrapper.
Be sure to select the Nanobiotix stock listed on Euronext Paris (ISIN FR0011341205), and not the Nasdaq-traded ADS, which are not eligible for the PEA.
To avoid concentrating all of your investment on a single biotech, another approach is to allocate capital between Nanobiotix stock directly and an ETF focused on biotechnologies. Some sector ETFs provide exposure to companies such as Amgen, Vertex Pharmaceuticals, or Biogen, with broader diversification. This allocation does not remove sector risk, but it reduces dependence on the clinical results of a single company. Online brokers such as ProRealTime x Interactive Brokers, Saxo Bank or Freedom24 offer a wide range of ETFs with fee-free ETF investment plans for the latter two.
The information from Cafedelabourse.com and its publications is provided for educational purposes. They do not constitute investment recommendations. The reader should assess risks before performing any transaction. The reader alone is responsible for their investment decisions.
Past performance is not indicative of future results. Investing in stocks carries a risk of capital loss.
All of our information is, by nature, generic. They do not take into account your personal situation and do not constitute personalized recommendations for the purpose of executing transactions and cannot be equated to financial investment advisory services. The reader is solely responsible for using the information provided, with no recourse against the publishing company Cafedelabourse.com. The publisher’s liability cannot be engaged under any circumstances in case of error, omission or ill-timed investment.
